JAN 27, 2017 11:31 AM PST

Bezlotoxumab for recurrent C. difficile infections

WRITTEN BY: Kerry Evans

Clostridium difficile often infects hospitalized patients who have undergone antibiotic therapy. These bacteria infect the gut, causing diarrhea and colitis. These infections are serious and can even be fatal.

 

Although C. difficile can be treated with antibiotics, the infection often recurs.  

 

C. difficile bacteria

 

According to study author Mark Wilcox from the University of Leeds, “about one in four patients who have been treated with antibiotics for an initial C.diff infection will go on to have a repeat infection. These repeat infections are more difficult to treat, have more severe outcomes for the patient, and are associated with more hospitalisations. It is important to treat the first episodes of C. diff infection optimally, as each recurrence increases the chance of another episode even more.”

 

With this in mind, Wilcox and colleagues conducted two phase 3 trials to determine if monoclonal antibodies against C. difficile toxins could help prevent recurrent infections. Bezlotoxumab is a monoclonal antibody against toxin B, and actoxumab is a monoclonal antibody for toxin A.

 

The studies (MODIFY I and MODIFY II) were conducted with 2,655 adults at 322 sites in 30 countries. Participants received, in addition to standard antibiotic treatment (vancomycin, metronidazole, or fidaxomicin), bezlotoxumab, actoxumab, both bezlotoxumab and actoxumab, or a placebo (saline).

 

In the MODIFY I study, infection recurred (within 12 weeks of initial cure) in 28% of participants receiving the placebo, but only in 17% of people receiving bezlotoxumab. The rates were very similar in the MODIFY II study. The effect of actoxumab and bezlotoxumab together was similar to that of bezlotoxumab alone. In addition, the rates of recurrent infection in high-risk patients were lower for the bezlotoxumab group and the combined actoxumab/bezlotoxumab groups compared to the placebo group.

 

The researchers also looked at an endpoint they termed “sustained cure,” defined as initial cure with no recurrent infection over the next 12 weeks. In pooled data from the MODIFY I and II studies, 64% of participants in the bezlotoxumab group achieved sustained cure, compared to 58% in the actoxumab/bezlotoxumab group and 54% in the placebo group.

 

Overall, bezlotoxumab lowered the risk of first post-treatment relapse by 40% compared to standard treatment alone.

 

Bezlotoxumab is approved by the FDA and will soon be available to doctors treating C. difficile infections. However, in a commentary on this study, John G. Bartlett questions whether using bezlotoxumab is really cost-effective. He notes that, while effective, bezlotoxumab may not need to become the standard of care - fidaxomicin already effectively prevents recurrent infections, and antibiotic resistance has not been an issue for treating C. difficile infections.

 

This new treatment regimen may, however, benefit high-risk patients - those older than 65, people with kidney issues, or those already on antibiotics, for example. "The studies showed that bezlotoxumab was particularly effective in those patients with risk factors for poor outcome, including older age, immunocompromise, and severe infection," says Wilcox.

 

 

Sources: NEJM article, NEJM commentary, Science Daily

 
About the Author
  • Kerry received a doctorate in microbiology from the University of Arkansas for Medical Sciences.
You May Also Like
DEC 04, 2019
Microbiology
DEC 04, 2019
Potentially Deadly Superbugs Lurk in Many Makeup Bags
New research has found that many makeup products, including mascara, lip gloss, and beauty blenders are contaminated with bacteria....
DEC 08, 2019
Microbiology
DEC 08, 2019
Bacterial Hydrogel Shows Promise as a Healer of Gut Wounds
When we get a cut, we easily put a bandage on it and it heals, but internal wounds can be much harder to treat....
DEC 18, 2019
Clinical & Molecular DX
DEC 18, 2019
Germs don't stand a chance with new AI-powered diagnostic platform
We are steadily losing our edge in the war against infectious bacteria. A huge surge in antibiotic resistance is threatening healthcare and agricultural in...
DEC 23, 2019
Cell & Molecular Biology
DEC 23, 2019
An Antioxidant Found in Green Tea Can Fight Tuberculosis
In 2018, around ten million people around the globe were sickened by tuberculosis (TB) and about 1.5 million people were killed by tuberculosis....
FEB 14, 2020
Microbiology
FEB 14, 2020
CDC Director Expects Coronavirus to Find a "Foothold"
The novel coronavirus that emerged in Wuhan, Hubei Province, China has now infected over 64,000 people....
FEB 18, 2020
Microbiology
FEB 18, 2020
Coronavirus Illness COVID-19 Has Now Caused Over 2,000 Deaths
The outbreak of COVID-19 disease caused by a novel coronavirus called SARS-CoV-2 has now claimed 2,005 lives and caused at least 75,079 cases....
Loading Comments...